57
Views
16
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial

, , , , , , & show all
Pages 103-111 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Thomas R. Einarson & Michiel E. H. Hemels. (2013) Validation of an economic model of paliperidone palmitate for chronic schizophrenia. Journal of Medical Economics 16:11, pages 1267-1274.
Read now
A Aleksander Araszkiewicz, Katarzyna Szabert, Brian Godman, Magdalena Wladysiuk, Corrado Barbui & Alan Haycox. (2008) Generic olanzapine: health authority opportunity or nightmare?. Expert Review of Pharmacoeconomics & Outcomes Research 8:6, pages 549-555.
Read now

Articles from other publishers (14)

Mônica Kayo & Denise Razzouk. 2017. Mental Health Economics. Mental Health Economics 313 322 .
Benno Hartung, Stephanie Sampson & Stefan Leucht. (2015) Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Soe Soe Thwin, Eric Hermes, Robert Lew, Paul Barnett, Matthew Liang, Danielle Valley & Robert Rosenheck. (2013) Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Research 209:3, pages 291-296.
Crossref
Neil Krishan Aggarwal, Haojuan Tao, Ke Xu, Elina Stefanovics, Liu Zhening & Robert A. Rosenheck. (2011) Comparing the PANSS in Chinese and American inpatients: Cross-cultural psychiatric analyses of instrument translation and implementation. Schizophrenia Research 132:2-3, pages 146-152.
Crossref
Magda Wladysiuk, Aleksander Araszkiewicz, Brian Godman, Katarzyna Szabert, Corrado Barbui & Alan Haycox. (2011) Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland. Applied Health Economics and Health Policy 9:2, pages 101-110.
Crossref
Sandra G. Resnick & Robert A. Rosenheck. 2010. Antipsychotic Trials in Schizophrenia. Antipsychotic Trials in Schizophrenia 120 132 .
Robert A. Rosenheck & Douglas L. Leslie. 2010. Antipsychotic Trials in Schizophrenia. Antipsychotic Trials in Schizophrenia 57 79 .
Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Sandra Schwarz, Paranthaman Sethupathi Bhoopathi, Werner Kissling & Stefan Leucht. (2009) Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Martin Knapp & Denise Razzouk. 2009. Schizophrenia. Schizophrenia 347 361 .
S. Mohamed, R. Rosenheck, J. McEvoy, M. Swartz, S. Stroup & J. A. Lieberman. (2008) Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 35:2, pages 336-346.
Crossref
Martin Knapp & Denise Razzouk. (2008) Costs of schizophrenia. Psychiatry 7:11, pages 491-494.
Crossref
Sandra G. Resnick, Robert A. Rosenheck, Jose M. Canive, Cyril De Souza, T. Scott Stroup, Joseph McEvoy, Sonia Davis, Richard SE Keefe, Marvin Swartz & Jeffrey Lieberman. (2008) Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. The Journal of Behavioral Health Services & Research 35:2, pages 215-225.
Crossref
Rajiv Tandon, R.H. Belmaker, Wagner F. Gattaz, Juan J. Lopez-IborJr.Jr., Ahmed Okasha, Bruce Singh, Dan J. Stein, Jean-Pierre Olie, W. Wolfang Fleischhacker & Hans-Juergen Moeller. (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 100:1-3, pages 20-38.
Crossref
David Cunningham Owens. (2018) How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Advances in Psychiatric Treatment 14:1, pages 17-28.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.